Related Experiment Video
Updated: Mar 13, 2026
08:32
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
1.4K
Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?
Brian Budke1, Wei Lv2, Alan P Kozikowski2
1Department of Radiation and Cellular Oncology, University of Chicago, 5841 S. Maryland Ave., Chicago, IL, 60637, USA.
Chemmedchem
|October 27, 2016
Summary
RAD51 protein overexpression in cancer fuels tumor resistance to therapies. Targeting RAD51 function offers a promising strategy for developing novel anticancer treatments by disrupting DNA repair and replication stability.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Homologous recombination (HR) is a critical DNA repair pathway conserved across species.
- Overexpression of the RAD51 protein, a key player in HR, is frequently observed in malignant cells.
- RAD51's roles in repairing DNA double-strand breaks (DSBs) and stabilizing replication forks are crucial for genome stability.
Purpose of the Study:
- To provide an overview of recent advancements in developing cancer therapeutics targeting RAD51 protein function.
- To discuss the challenges and perspectives associated with these evolving anticancer strategies.
Main Methods:
- Review of recent scientific literature on RAD51-targeted cancer therapies.
- Analysis of RAD51's dual roles in DNA repair and replication stress response.
- Discussion of therapeutic strategies aimed at inhibiting RAD51 activity.
Main Results:
- Upregulation of RAD51 in cancer cells contributes to resistance against DNA-damaging therapies.
- Targeting RAD51 function presents a viable approach for overcoming treatment resistance.
- Several therapeutic strategies targeting RAD51 are under investigation.
Conclusions:
- Targeting RAD51 is a promising avenue for novel cancer therapeutics.
- Overcoming challenges in RAD51-targeted therapy development is essential for clinical success.
- Further research is needed to fully exploit RAD51 as an anticancer target.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:15Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:46Electron Transport Chain: Complex I and II
19.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.4K
01:10Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
02:53Adaptive Mechanisms in Cancer Cells
7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K